XML 91 R38.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information - Schedule of Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Information [Line Items]    
Research and development expenses (excluding stock compensation) $ 6,266 $ 2,811
General and administrative expenses (excluding stock compensation) 1,555 1,541
Stock-based compensation expense 4,725 2,400
Recapitalization of common stock 26,004
Other expense – direct listing offering costs 1,164
Net Income (Loss) (8,985) (30,356)
Lysosomal Storage Disorders Segment [Member]    
Segment Information [Line Items]    
Research and development expenses (excluding stock compensation) (1,922) (1,077)
General and administrative expenses (excluding stock compensation) (1,174) (875)
Stock-based compensation expense (4,725) (2,400)
Recapitalization of common stock (26,004)
Other expense – direct listing offering costs (1,164)
Net Income (Loss) $ (8,985) $ (30,356)